aibioAIM ImmunoTech satisfies Streeterville note in full through share exchanges
Tickers AIM
AIM ImmunoTech converted approximately $1,224,341 of a February 16, 2024 promissory note held by Streeterville Capital, LLC into 5,065,840 shares, and the note was satisfied in full as of September 3, 2026.
Key facts
- Company
- AIM ImmunoTech Inc. (AMEX: AIM)
- News type
- Debt Financing
- Primary source
- AIM ImmunoTech Inc. 8-K (2026-09-04)
AIM ImmunoTech Inc. satisfied in full a promissory note held by Streeterville Capital, LLC after converting approximately $1,224,341 of it into 5,065,840 shares of common stock, according to a Form 8-K filed September 4, 2026. The filing reports the transactions under Item 1.01, the termination of a material definitive agreement under Item 1.02, the unregistered share issuance under Item 3.02, and the exhibit list under Item 9.01.
Between August 31, 2026 and September 3, 2026, the company entered into five exchange agreements with the lender. For each one it also entered into a corresponding partitioned promissory note. The notes relate to a Promissory Note dated February 16, 2024. The conversions were made at an average conversion price of approximately $0.24 per share.
As of September 3, 2026, the filing says, the Promissory Note was satisfied in full and no amounts remain owing under it. The 8-K reports the termination under Item 1.02 by reference to the exchange agreements and the partitioned notes.
Approval and exemption
Stockholders had approved the conversion or other satisfaction of the note at a special meeting held on July 15, 2026, under NYSE American Company Guide Sections 713(a) and 713(b). The filing says the shares were or will be issued under Section 3(a)(9) of the Securities Act, an exemption for exchanges with an existing holder where no commission is paid for soliciting the exchange.
The 8-K points readers to the company's quarterly report on Form 10-Q for the quarter ended June 30, 2026, for more information about the company and the lender. The form of exchange agreement is filed as Exhibit 10.1 to the 8-K.
About AIM ImmunoTech
AIM ImmunoTech is an immuno-pharma company headquartered in Ocala, Florida, focused on therapeutics for multiple types of cancers, viral diseases and immune-deficiency disorders. Its annual report on Form 10-K, filed March 27, 2026, says its flagship product, Ampligen (rintatolimod), is a double-stranded RNA molecule that has not been approved by the FDA or marketed in the United States. Ampligen is approved for commercial sale in the Argentine Republic for severe Chronic Fatigue Syndrome.
The 10-K says the company has made the business decision to focus on Ampligen for late-stage pancreatic cancer. It describes the DURIPANC study, an investigator-initiated Phase 2 study of Ampligen with AstraZeneca's Imfinzi (durvalumab) in metastatic pancreatic cancer patients with stable disease after FOLFIRINOX. Up to 25 subjects are expected in the Phase 2 portion, and eighteen patients have been enrolled. In March 2026 the company announced an agreement with the PPD clinical research business of Thermo Fisher Scientific to design its anticipated Phase 3 trial.
Financial position
The XBRL data show revenue of $88,000 for 2025, against $170,000 for 2024. Research and development expense was $3.9 million in 2025 and $6.2 million in 2024. The net loss was $14.0 million for 2025 and $17.3 million for 2024. Cash used in operations was $11.0 million in 2025 and $14.9 million in 2024.
Year-end cash and cash equivalents were $3.0 million at the end of 2025, according to a Form 10-Q filed August 7, 2026, compared with $1.7 million at the end of 2024. Short-term investments were $62,000 at the end of 2025 and $2.3 million at the end of 2024. The 10-Q reports cash and cash equivalents of $9.9 million at June 30, 2026.
Debt gone, shares added
Clearing the note removes a creditor but does it with stock: 5,065,840 new shares at an average of about $0.24. The filing gives no total share count after the issue. The science supporting the company's pancreatic cancer focus is early. DURIPANC is an investigator-initiated Phase 2 study with eighteen of up to 25 patients enrolled, and the sources report no efficacy results. The 10-K's reference to clinical success rests on an early access program and that ongoing trial. Ampligen is not approved in the United States, and the 10-K says only that the company believes a Phase 3 will be possible, which is a belief, not a regulatory step. Revenue was $88,000 in 2025 against a net loss of $14.0 million and cash used in operations of $11.0 million.